Complement C4 is often checked in lupus because it participates near the beginning of the classical complement pathway—the route commonly activated by antibody-antigen immune complexes. When that pathway is active, C4 may be consumed and its blood concentration may fall. A low C4 can support evidence of active systemic lupus erythematosus, but it cannot by itself diagnose lupus, identify the affected organ, or prove that treatment should change.
C4 has an added interpretive challenge: some people naturally make less of it because the number and type of their C4 genes vary. Their result may stay below the laboratory range even when lupus is quiet. C4 also falls in conditions such as hereditary angioedema, cryoglobulinemia, infection, and other immune-complex disorders. The most useful reading therefore compares the value with the patient’s established baseline and considers C3, CH50, anti-dsDNA, symptoms, urine findings, kidney function, and medications.
- Low C4 often reflects classical-pathway activation, but it is not specific to lupus.
- A falling value may support a flare when objective clinical or kidney findings change at the same time.
- Persistently low C4 can reflect genetic copy number rather than ongoing disease activity.
- Normal C4 does not exclude active lupus or lupus nephritis.
- C4 concentration, C4d activation products, and CH50 pathway function are different tests.
Table of Contents
- Why C4 is a distinct complement marker
- How lupus changes C4
- Three common low-C4 patterns
- C4 in kidney and flare assessment
- Conditions beyond lupus that lower C4
- Interpreting C4 with the rest of the panel
- Next steps after an abnormal result
Why C4 is a distinct complement marker
The complement system consists of interacting proteins that recognize threats, mark targets for clearance, amplify inflammation, and help form the membrane attack complex. Complement can be initiated through classical, lectin, or alternative pathways. C4 is used by the classical and lectin pathways but is not an initiating component of the alternative pathway.
In the classical pathway, antibody-containing immune complexes activate C1. Activated C1 cleaves C4, allowing a C4 fragment to bind nearby surfaces and participate in formation of the C3 convertase. The cascade then reaches C3 and the shared terminal pathway. This position makes C4 especially informative when antibody-driven classical-pathway activation is suspected.
A routine C4 test measures the amount of circulating complement component 4. It does not directly measure the amount being activated at that moment. Nor does it measure the total ability of the pathway to function. The related tests answer different questions:
- C3 measures a central protein used by all three pathways.
- CH50 assesses the combined function of the classical and terminal pathways.
- C4d is a breakdown or activation product that can be measured in specialized blood tests, on cells, or in tissue in selected settings.
- C1 inhibitor testing evaluates a regulator relevant to hereditary or acquired angioedema.
C4 biology is genetically complex. Humans have C4A and C4B genes within a variable genomic region, and individuals can carry different numbers of copies. Lower C4A or total C4 copy number can produce a naturally lower serum C4 and has also been associated with susceptibility to lupus. Thus, low C4 can sometimes represent an inherited background risk marker rather than current consumption.
The laboratory method usually measures C4 by immunoassay and reports a concentration in milligrams per deciliter, grams per liter, or another unit. Reference ranges vary. A result from one laboratory should not be directly compared with a differently calibrated platform without checking units and intervals.
How lupus changes C4
Lupus autoantibodies may bind nuclear antigens released from injured or dying cells. The resulting immune complexes can circulate or deposit in tissues. When they activate the classical pathway, C4 is cleaved and consumed. If consumption exceeds replacement, the measured blood concentration falls.
This is why C4 is included in many lupus blood test panels. Low C3 and/or C4 also contributes to the immunologic domain of the 2019 EULAR/ACR classification criteria. Classification supports research consistency; it does not mean a single low complement result establishes a clinical diagnosis.
C4 may be helpful at several points:
During diagnostic evaluation
Low C4 can strengthen an immune-complex pattern when a patient also has compatible symptoms, a positive ANA, lupus-specific antibodies, blood-count abnormalities, or kidney findings. It is supportive evidence, not a screening result that should be interpreted alone in someone without a clinical reason for testing.
During established lupus monitoring
Some patients have a personal pattern in which C4 drops during active disease and rises toward baseline after treatment. Serial measurement can then contribute to disease-activity assessment. The pattern is more reliable when it has repeated across prior flares.
When a silent organ flare is possible
Lupus nephritis can develop with few symptoms. A decline in C4 may prompt closer review of urinalysis, urine protein, creatinine, blood pressure, and anti-dsDNA. The complement result acts as an alert, not as proof of kidney inflammation.
When symptoms and serology disagree
A patient may feel worse while C4 remains unchanged, or C4 may fall while the patient feels well. This mismatch is common enough that clinicians must assess both sides. Pain, fatigue, fever, rash, and cognitive symptoms can have inflammatory and noninflammatory causes. Conversely, kidney abnormalities may appear before a person feels ill.
C4 does not reliably identify every flare. Complement production can increase during inflammation, partially masking consumption. Some lupus phenotypes do not strongly activate the classical pathway. Other patients begin with a genetically low baseline that leaves little room for a visible decline.
Three common low-C4 patterns
Thinking in patterns is more useful than treating all low results as equivalent.
Pattern 1: C4 falls from baseline with other evidence of activity
This is the pattern most suggestive of acquired complement consumption. Examples include a falling C4 with rising anti-dsDNA, lower C3, new inflammatory rash, serositis, cytopenias, or urine abnormalities. The more objective findings align, the more likely the result reflects active lupus.
Even here, C4 does not indicate severity on its own. A value just below range could accompany significant kidney disease, while a very low value could occur with a clinically milder manifestation. Organ assessment determines urgency.
Pattern 2: C4 remains chronically low while the patient is stable
A persistently low, relatively flat C4 may reflect C4 gene copy number, a constitutional baseline, chronic low-grade consumption, or another ongoing condition. Clues include years of similar values, stable C3 and CH50 patterns, no relationship to symptoms, and no corresponding change in urine or organ tests.
Genetic C4 variation is not usually investigated in routine lupus care. It may be considered when interpretation remains difficult, especially in early-onset autoimmunity or suspected complement deficiency. More often, clinicians simply recognize that C4 is not a dependable activity marker for that individual and monitor other measures.
Pattern 3: C4 is very low with a specific non-lupus clinical clue
Examples include recurrent swelling without hives, cryoglobulinemic symptoms, severe infection, or another immune-complex disease. In hereditary angioedema due to C1 inhibitor deficiency or dysfunction, C4 is commonly low because uncontrolled classical-pathway-related activation consumes it. C4 is a screening clue, not the confirmatory test; C1 inhibitor antigen and function are required.
The same patient can move between patterns. Someone with a genetically low baseline can still consume additional C4 during a lupus flare. This is why personal trend and accompanying tests remain essential.
C4 in kidney and flare assessment
Kidney risk is one of the main reasons complement results receive close attention in lupus. Immune complexes can deposit in glomeruli and activate complement, producing inflammation that may lead to proteinuria, blood in urine, reduced filtration, and chronic scarring.
A low C4 becomes more concerning for lupus nephritis when it occurs with:
- New proteinuria or a rising urine protein-to-creatinine ratio.
- Microscopic hematuria or cellular casts.
- Rising creatinine or declining estimated glomerular filtration rate.
- New hypertension or edema.
- Lower C3 or CH50.
- Rising anti-dsDNA antibodies.
Urine and kidney tests are more direct than C4. A person can have low complement without nephritis, and nephritis can occur with normal complement. Serum creatinine may also remain normal early, so routine urinalysis and protein quantification are important even when kidney function looks preserved.
If findings suggest clinically significant nephritis, a kidney biopsy may be recommended. Biopsy distinguishes patterns such as proliferative and membranous disease and separates active inflammation from chronic damage. C4 cannot provide that information. Treatment choices are based on biopsy class, clinical severity, response history, fertility plans, comorbidities, and patient preferences.
For flare prediction, serial C4 can add useful context but has only moderate performance. A decline may precede a flare in some patients, yet false alarms and missed flares occur. The most defensible strategy is multivariable monitoring rather than reliance on one biomarker.
In pregnancy, interpretation becomes more nuanced. Complement normally rises as pregnancy progresses. A failure of C4 to increase, or a decline from the patient’s conception baseline, may be informative even when the value remains inside a standard range. Prior nephritis, blood pressure, urine protein, anti-dsDNA, fetal assessment, and the possibility of preeclampsia must all be considered.
Conditions beyond lupus that lower C4
Low C4 is not a lupus-specific finding. Important alternatives include:
Hereditary or acquired angioedema
C1 inhibitor deficiency or dysfunction permits excessive activation and typically lowers C4. Patients may have recurrent swelling of the skin, abdomen, airway, or genital tissues, usually without hives. Acquired C1 inhibitor deficiency can occur with certain lymphoproliferative or autoimmune conditions. Sudden throat or tongue swelling is a medical emergency.
Cryoglobulinemia
Cryoglobulins are immunoglobulins that precipitate in cooler temperatures and can form immune complexes. Mixed cryoglobulinemia often produces very low C4, sometimes with purpura, neuropathy, joint symptoms, kidney disease, or hepatitis C infection. Specimen collection for cryoglobulins requires careful warm handling.
Infection and immune-complex disease
Endocarditis and other chronic infections can consume complement. Some glomerulonephritides, vasculitides, and autoimmune diseases also activate the classical pathway. Fever in an immunosuppressed patient should not be presumed to be lupus merely because C4 is low.
Liver disease and protein loss
Advanced liver dysfunction can reduce complement synthesis. Kidney or gastrointestinal protein loss may lower circulating proteins. Albumin, liver tests, urine protein, and clinical history help identify these mechanisms.
Inherited complement deficiency
Complete deficiencies of early classical components, including C4, are rare and strongly associated with lupus-like autoimmunity and infection susceptibility. A repeatedly absent or extremely low functional pathway, early-onset disease, unusual infections, or a family history may prompt CH50, AH50, individual component, and genetic evaluation.
Medication effects
Complement-targeted medicines can alter pathway activity and sometimes concentrations or activation products. The direction and magnitude depend on the drug target. Results should be interpreted using the relevant treatment-monitoring protocol.
Interpreting C4 with the rest of the panel
The relationship among C3, C4, and CH50 can suggest where complement activity is occurring, although it rarely provides a complete diagnosis.
| Pattern | Possible meaning |
|---|---|
| Low C3 and low C4 | Classical-pathway consumption from active immune-complex disease, including lupus; broad consumption or reduced synthesis may also contribute |
| Normal C3 and low C4 | Classical-pathway-predominant consumption, hereditary angioedema, cryoglobulinemia, or genetically low C4 |
| Low C3 and normal C4 | Alternative-pathway activation, severe infection, selected complement-mediated kidney diseases, or lupus with an atypical pattern |
| Low CH50 with normal C3 and C4 | Possible functional deficiency of another classical or terminal component, complement blockade, assay issue, or specimen problem |
| Stable low C4 with no clinical changes | Constitutional baseline or chronic process may be more likely than a new flare |
Anti-dsDNA may track lupus activity in some patients, particularly kidney disease, but assay methods differ and not everyone has the antibody. Blood counts can reveal leukopenia, anemia, or thrombocytopenia. Urinalysis, urine protein, creatinine, and blood pressure assess kidney involvement. Clinical examination establishes whether a rash, joint inflammation, serositis, neurologic change, or another manifestation is actually present.
C4d deserves separate mention because it is sometimes confused with serum C4. C4d is generated after C4 activation and may be detected on blood cells or in kidney tissue. Research suggests that activation-product measures can provide information not captured by protein concentration alone. They are not universally standardized or available and do not replace routine clinical assessment.
A high C4 result is generally nonspecific. C4 can rise with acute-phase production during inflammation or infection. An elevated concentration is not usually used to diagnose a lupus flare and does not mean the immune system is “overactive” in a simple sense.
Next steps after an abnormal result
When C4 is newly low, clinicians usually verify the context before acting. The review may include prior C4 values, C3, CH50, anti-dsDNA, complete blood count, kidney and liver tests, urinalysis, urine protein, blood pressure, symptoms, medication changes, and infection risk.
The next step might be:
- Repeat testing if the change is small or unexpected.
- More urgent kidney evaluation if urine or creatinine has changed.
- C1 inhibitor studies when recurrent angioedema is suspected.
- Cryoglobulin, infection, or liver evaluation when the clinical picture points elsewhere.
- Immunology referral for possible inherited complement deficiency.
- No treatment change if the value is a stable personal baseline and objective disease is quiet.
Questions to ask include:
- Is this lower than my usual C4, or is it chronically low?
- Did C3, CH50, or anti-dsDNA change at the same time?
- Are my urine protein, sediment, creatinine, and blood pressure normal?
- Could genetic C4 copy number explain my baseline?
- Do my symptoms suggest angioedema, infection, or cryoglobulinemia rather than lupus activity?
- Which objective finding would justify treatment adjustment?
- How often should complement and urine monitoring be repeated?
Seek prompt care for reduced urine output, rapidly worsening swelling, severe hypertension, chest pain, neurologic symptoms, high fever while immunosuppressed, or swelling of the tongue or throat.
C4 is most valuable when it is treated as a longitudinal clue. A meaningful fall can lead to earlier organ assessment; a stable low baseline can prevent unnecessary escalation. The distinction comes from context, not the color or flag printed beside the laboratory value.
References
- Complement as a Biomarker for Systemic Lupus Erythematosus (2023, PubMed)
- The Complement System and Human Autoimmune Diseases (2023, PubMed)
- Strong Association of Combined Genetic Deficiencies in the Classical Complement Pathway With Risk of Systemic Lupus Erythematosus (2022, PubMed)
- EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update (2024, PubMed)
- KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis (2024, PubMed)
- Complement Levels During the First Trimester Predict Disease Flare in Systemic Lupus Erythematosus Pregnancy: A Network Meta-Analysis (2023, PubMed)
Disclaimer
This article is for educational purposes and does not diagnose lupus activity, kidney disease, angioedema, or complement deficiency. C4 must be interpreted by a qualified clinician with the patient’s baseline, symptoms, C3, CH50, urine and kidney tests, medications, and other relevant studies. Airway swelling, severe infection symptoms, neurologic changes, or signs of acute kidney disease require urgent medical care.
